Published in Haematologica on September 01, 2006
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 1.55
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med (2010) 1.52
Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res (2010) 1.41
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer (2010) 1.13
Vdelta2 T-lymphocyte responses in cord blood samples from Italy and Côte d'Ivoire. Immunology (2008) 0.89
Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw. Int J Oral Sci (2014) 0.83
Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ (2016) 0.82
Increased human defensine levels hint at an inflammatory etiology of bisphosphonate-associated osteonecrosis of the jaw: an immunohistological study. J Transl Med (2011) 0.80
Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw. Calcif Tissue Int (2012) 0.78
Establishment of an Animal Model of Bisphosphonate-Related Osteonecrosis of the Jaws in Spontaneously Diabetic Torii Rats. PLoS One (2015) 0.78
Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw? J Cancer Res Clin Oncol (2014) 0.77
The effects of zoledronate on monocyte-derived dendritic cells from melanoma patients differ depending on the clinical stage of the disease. Hum Vaccin Immunother (2014) 0.76
Osteoinductivity of demineralized bone matrix is independent of donor bisphosphonate use. J Bone Joint Surg Am (2011) 0.76
Bisphosphonates Inhibit Pain, Bone Loss, and Inflammation in a Rat Tibia Fracture Model of Complex Regional Pain Syndrome. Anesth Analg (2016) 0.75
Zoledronic acid modulates function and differentiation of myeloid cells. Haematologica (2006) 0.75
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44
Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun (2004) 3.21
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol (2007) 2.72
Autocrine formation of hepcidin induces iron retention in human monocytes. Blood (2007) 2.50
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood (2013) 2.34
Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity (2011) 2.20
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med (2014) 2.07
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02
CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol (2005) 1.83
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 1.74
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells. J Exp Med (2013) 1.70
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol (2007) 1.63
Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood (2011) 1.63
IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol (2010) 1.52
Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes (2011) 1.52
Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol (2014) 1.52
Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol (2004) 1.50
Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis (2012) 1.49
EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol (2011) 1.46
Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res (2004) 1.46
Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Hum Pathol (2005) 1.43
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood (2013) 1.42
GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood (2009) 1.37
Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut (2010) 1.30
Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology (2003) 1.30
Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol (2002) 1.27
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol (2004) 1.26
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology (2010) 1.23
The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A (2005) 1.23
High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol (2006) 1.18
Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun (2007) 1.16
A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. Am J Gastroenterol (2010) 1.15
Peripheral infusion of rat bone marrow derived endothelial progenitor cells leads to homing in acute lung injury. Respir Res (2007) 1.14
Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer (2002) 1.13
Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr Pharm Des (2010) 1.08
Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol (2004) 1.08
Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp (Warsz) (2013) 1.08
Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. Obesity (Silver Spring) (2009) 1.08
The Dickkopf-homolog 3 is expressed in tumor endothelial cells and supports capillary formation. Int J Cancer (2008) 1.08
Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol (2005) 1.07
Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology (2008) 1.07
Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur J Immunol (2009) 1.07
Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation (2007) 1.07
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett (2006) 1.07
Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med (2011) 1.06
Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer (2004) 1.05
Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol (2005) 1.04
The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res (2010) 1.04
Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol (2008) 1.03
Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer (2012) 1.03
The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol (2005) 1.01
Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia. Genes Chromosomes Cancer (2002) 1.01
Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer (2011) 1.00
Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol (2011) 0.99
Alternative splicing of vasohibin-1 generates an inhibitor of endothelial cell proliferation, migration, and capillary tube formation. Arterioscler Thromb Vasc Biol (2008) 0.98
Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol (2009) 0.98
Endothelial progenitor cells: a source for therapeutic vasculogenesis? J Cell Mol Med (2004) 0.97
RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol (2005) 0.97
Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Am J Physiol Gastrointest Liver Physiol (2005) 0.96
Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab (2013) 0.96
Visceral adipose tissue attacks beyond the liver: esophagogastric junction as a new target. Gastroenterology (2010) 0.95
Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology (2011) 0.95
Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide-dependent mechanism. Circ Res (2009) 0.95
Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. J Hepatol (2013) 0.95
Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum Pathol (2007) 0.95
Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo. BMC Cancer (2009) 0.95
Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine. Immunol Cell Biol (2011) 0.94
Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry. BMC Res Notes (2008) 0.94
The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol (2009) 0.93